
Novartis says an acquired Avidity gene muscle drug shows promise in early-mid study
The biotech deal's $12 billion bet is starting to pay off, at least early, for a rare genetic myopathy.
By Mohammed Al-Shehri·· 3 min
1 briefing · “novartis”

The biotech deal's $12 billion bet is starting to pay off, at least early, for a rare genetic myopathy.